Artiklar

{{ window.visitor.ipAccess.corporateClient.name }}
Welcome to our Corporate client solution

Your IP is registered with the company mentioned above and provides access to Life Science Sweden.
Click here to go to sign-up

Sortering: Sida Sida av 1

He is zooming in on topical preparations
November 22 2022
According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting approval for its new GMP facility.
Swedish breakthrough in Alzheimer’s: “We can finally present great data”
November 14 2022
Treatments for Alzheimer’s disease are currently among the hottest topics in drug development. Two Swedish research companies with high ambitions and successes in the field participated in Bioscience 2022 conference at Life City in Hagastaden, Stockholm.
FOKUS Patient turns international
September 20 2022
FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.
Life Science-podden: The perfect moment for an IPO
September 14 2022
When is the right time to go for an IPO? What strategy is recommended in today´s rather uncertain business climate when it comes to taking your life science company public?
Amorphous materials take centre stage when Orexo develops new formulations
August 16 2022
Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive properties of the material, and it also cracks some of the problems,” says the company’s
Gel av spindeltrådsprotein utvecklas för biomedicinsk användning
August 15 2022
Spindeltrådens märkliga egenskaper kommer till användning när svenska forskare undersöker nya, potentiella metoder för bland annat regenerativ medicin och läkemedelsformulering.
Elicera develops CAR-T against solid tumours – may become the first in the world
Marts 10 2022
Today, there are five EU-approved CAR-T therapies, all focused on different types of blood cancer, but no one has yet succeeded in making the method work against solid tumours. At Gothenburg-based Elicera, they are working relentlessly to succeed in that field as well. “It is the largest field, and the potential is enormous,” says the company’s CEO Jamal El-Mosleh.

Resultat per sida: Sida Sida av 1

BREAKING

{{ article.headline }}

0.078|instance-web04